Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?

Revolution Medicines (RVMD) shares soared on April 13 after the biotech firm said its pancreatic cancer drug, daraxonrasib, demonstrated an “unprecedented survival rate” in a Phase 3 clinical trial. 

The upward momentum helped RVMD break above its key moving averages (20-day and 50-day), indicating that near-term momentum is shifting in favor of the bulls.   

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.